N. Lynn Henry, MD, PhD, on Biomarkers for Systemic Therapy for Metastatic Breast Cancer

Newly updated guidance from ASCO focuses on advances in using biomarkers to direct systemic therapy for metastatic breast cancer.

“The Update Panel revisited recommendations from the 2015 guideline and expanded the scope of the guideline to address topics that have emerged since the publication of the 2015 guideline,” N. Lynn Henry, MD, PhD, Breast Oncology Disease Lead of the University of Michigan Rogel Cancer Center in Ann Arbor, and co-authors wrote in the guidance update document in the Journal of Clinical Oncology.

Source: https://www.medpagetoday.com/reading-room/asco/breast-cancer/100011